|
市場調査レポート
商品コード
1335915
ペニシリン製剤の世界市場規模、シェア、産業動向分析レポート:供給源別、活性領域別、流通経路別、投与経路別、地域別展望と予測、2023年~2030年Global Penicillin Drug Market Size, Share & Industry Trends Analysis Report By Source, By Spectrum of Activity, By Distribution Channel, By Route of Administration, By Regional Outlook and Forecast, 2023 - 2030 |
||||||
|
ペニシリン製剤の世界市場規模、シェア、産業動向分析レポート:供給源別、活性領域別、流通経路別、投与経路別、地域別展望と予測、2023年~2030年 |
出版日: 2023年07月31日
発行: KBV Research
ページ情報: 英文 284 Pages
納期: 即納可能
![]() |
ペニシリン製剤市場規模は2030年までに109億米ドルに達し、予測期間中にCAGR 3.6%の市場成長率で上昇すると予測されます。
KBV Cardinalのマトリックスに掲載された分析によると、ファイザー社が同市場におけるトップランナーです。2022年1月、Pfizer, Inc.はBecton, Dickinson, and Companyと提携し、抗菌薬を正しく使用するためのソリューションを開発しました。グラクソ・スミスクラインPLC(GSK)、ノバルティスAG、アボット・ラボラトリーズなどの企業は、この市場における主要なイノベーターです。
市場成長要因
細菌性疾患の発生率の増加
細菌によって引き起こされる病気は、人々の健康に大きな影響を与えます。誰でもこの病気にかかる可能性があり、その病気は細菌自体によって、あるいは細菌の存在に対する身体の反応によって引き起こされます。人間は、食物、水、空気、生物などを介して細菌に感染する可能性があります。この薬は、細菌が細胞壁を形成するのを助ける酵素を破壊します。異なる感染症には、異なるタイプのペニシリンが利用されます。アモキシシリン、アンピシリン、オーグメンチン、ペニシリンG、ペニシリンVはペニシリンの数種類です。上記の要素を考慮すると、拡大する細菌感染が市場の拡大を後押しすると予測されます。
効率的で最新の抗生物質に対する需要の増加
新しい抗生物質を開発し市場に投入するのは難しい仕事です。それでも、薬剤耐性疾患の脅威の高まりから人々を守るためには、それを達成しなければならないです。最初の抗生物質であるペニシリンが発見されて以来、現代医学は革命を遂げました。細菌は最終的に新しい薬に対する耐性を獲得します。また、スーパーバグとの終わりのない戦いに先んじるためには、診断法、ワクチン接種、より優れた予防、管理、モニタリングの開発が必要です。WHOによると、40~50種類の抗生物質が臨床開発段階にあります。その結果、抗生物質に対する需要の増加により、この市場は今後数年間で成長すると思われます。
市場抑制要因
多剤耐性(MDR)感染症の増加
ヘルスケアシステムに影響を及ぼしている最大の問題のひとつが、公衆衛生に重大なリスクをもたらす抗生物質耐性です。これらの菌株は、当初はホスピタリティのある病院内に限られていたが、現在では広く蔓延しています。抗生物質耐性の蔓延の原因として特定されているのは、世界化、水産養殖、複数の広域スペクトル薬の使用、畜産における抗生物質の過剰使用、適切な抗菌薬スチュワードシップの欠如などです。抗生物質耐性菌の増加を考えると、病気の治療に使用できる抗菌薬の数は少なくならざるを得ないです。
供給源の展望
供給源に基づいて、市場は天然ペニシリンと半合成ペニシリンに区分されます。天然ペニシリンは、2022年に市場でかなりの収益シェアを獲得しました。天然ペニシリンは、ボレリア、連鎖球菌、髄膜炎菌、ブドウ球菌、トレポネーマ、レプトスピラを含むグラム陽性菌とグラム陰性菌の両方に対して効率的です。ペニシリンVは経口用のみで、ペニシリンGは非経口用です。バクテロイデス・フラジリスを除き、これらの薬剤は嫌気性菌を含むグラム陽性菌が引き起こす疾患の診断に最もよく使用されます。
活性スペクトルの展望
活性スペクトルによって、市場はナロースペクトル、ブロードスペクトル、エクステンデッドスペクトルに分類されます。2022年には、広域スペクトルが市場で最大の売上シェアを占める。咽頭、耳、鼻副鼻腔、呼吸器(肺炎など)、尿路、皮膚・軟部組織、腸チフスなどの感染症はすべて、ペニシリンに関連する抗生物質の一種である広域スペクトルペニシリン系抗菌薬で治療できます。アンピシリンとそのエステル(バカピシリン、ピバンピシリン、タランピシリンなど)、アモキシシリン、コアモキシクラフ、メズロシリンなどが主な広域ペニシリン系抗生物質です。
流通チャネルの展望
流通チャネル別に見ると、市場は病院、ドラッグストア・小売薬局、オンラインプロバイダーに細分化されます。2022年の市場では、オンラインプロバイダー分野が突出した売上シェアを予測しています。ペニシリン製剤は複数のオンラインベンダーで販売されており、消費者はそれぞれのニーズに合ったブランド、用量、製剤を見つけることができます。さらに、24時間365日利用可能なプラットフォームのため、ユーザーはいつでもオンラインで買い物ができます。これらの要因がこのセグメントの成長を牽引していくと思われます。
投与経路の展望
投与経路に基づき、市場は経口剤と非経口剤に分類されます。2022年には、非経口投与セグメントが市場で最も高い売上シェアを占めました。重篤な細菌感染症の治療におけるペニシリン注射の使用増加や、ペニシリンG注射が主な治療法である梅毒の有病率の上昇による。心停止やアナフィラキシーショックの緊急時など、他のドラッグデリバリー方法よりも非経口投与が好まれる場合もあります。
地域別展望
地域別に見ると、市場は北米、欧州、アジア太平洋、LAMEAに分析されます。2022年には、アジア太平洋地域が最も高い収益シェアを獲得して市場をリードしました。この成長は、同地域の感染症罹患率の上昇とペニシリン製剤の需要増に関連しています。中国やインドのような国々の人口増加に伴い、アジア太平洋地域はペニシリン薬を含む抗生物質の最大市場の一つとなっています。さらに、アジア太平洋市場は、ヘルスケアコストの上昇、ヘルスケアインフラの改善、抗生物質の使用知識の増加、同地域における大手製薬会社の存在などの要因により、大きく拡大しています。
List of Figures
The Global Penicillin Drug Market size is expected to reach $10.9 billion by 2030, rising at a market growth of 3.6% CAGR during the forecast period.
Due to factors like the rising prevalence of infectious diseases, better healthcare infrastructure, key market players, and expanding awareness campaigns, North America region is expected to register more than 25% share of the market by 2030. According to Canadian Cancer Statistics, 45% of men and 43% of women in Canada will have cancer at some point in their lives. As the population of Canada ages and grows larger, the prevalence of new cancer cases has been continuously increasing in different cancers like throat, and lungs. Also, the growing elderly and pediatric populations in the region, who are more vulnerable to contracting infectious diseases because of low immunity, are anticipated to support the expansion of market.
The major strategies followed by the market participants are Partnerships as the key developmental strategy in order to keep pace with the changing demands of end users. For instance, In September, 2022, GlaxoSmithKline PLC partnered with Spero Therapeutics, Inc. to use Spero's tebipenem pivoxil hydrobromide antibiotic drug and allow GlaxoSmithKline to offer better treatment options for patients with urinary tract infections. Moreover, In March,2021, Cipla Limited entered a partnership with SIGA Technologies, Inc. to develop solutions for novel antibacterial drugs for countering biothreats.
Based on the Analysis presented in the KBV Cardinal matrix; Pfizer, Inc. is the forerunner in the Market. In January, 2022, Pfizer, Inc. came into partnership with Becton, Dickinson, and Company to develop solutions for the correct use of antimicrobial drugs. Companies such as GlaxoSmithKline PLC (GSK), Novartis AG, Abbott Laboratories are some of the key innovators in the Market.
Market Growth Factors
Increased Incidence of Bacterial Illness
Diseases caused by bacteria significantly impact the public's health. Anybody may acquire the disease, which can be brought on either by the organism itself or by the body's reaction to its existence. Humans can contract bacteria via food, water, the air, or living things. The medication destroys the enzymes that help bacteria form their cell walls. For different infections, different types of penicillin are utilized. Amoxicillin, ampicillin, Augmentin, penicillin G, and penicillin V are a few varieties of penicillin. In consideration to the above-mentioned elements, it is projected that the expanding bacterial infection will boost the expansion of the market.
Increasing Demand for Efficient and Modern Antibiotics
Developing and bringing new antibiotics to market is a difficult task. Still, it must be accomplished if the person is better protected against the rising threat of drug-resistant illnesses. Modern medicine has revolutionized since the first antibiotic, penicillin, was discovered. Bacteria will ultimately acquire resistance to the new medications. Also, they require advancements in creating diagnostics, vaccinations, and better prevention, control, and monitoring to stay ahead of the never-ending battle against superbugs. According to the WHO, 40 to 50 antibiotics are in clinical development. As a result, this market will grow in the next years due to the increasing demand for antibiotics.
Market Restraining Factors
Rise In Multi-Drug Resistant (MDR) Infections
One of the biggest issues affecting the healthcare system is antibiotic resistance, which presents a significant risk to public health. These strains were initially isolated to the hospital environment but are now prevalent. The causes identified as causing the spread of antibiotic resistance include globalization, aquaculture, the use of several broad-spectrum drugs, excessive use of antibiotics in animal husbandry, and a lack of proper antimicrobial stewardship. Given the rise in antibiotic-resistant organisms, there must be fewer antimicrobial medicines available to treat diseases.
Source Outlook
On the basis of source, the market is segmented into natural penicillin, and semisynthetic penicillin. The natural penicillin acquired a substantial revenue share in the market in 2022. Natural penicillins are efficient against both gram-positive and gram-negative bacteria, including Borrelia, streptococci, meningococci, staphylococci, Treponema, and Leptospira. Penicillin V is only for oral use, and penicillin G is for parenteral use. Except for Bacteroides fragilis, these medications are most often used to diagnose diseases brought on by gram-positive bacteria, including anaerobes.
Spectrum of Activity Outlook
By spectrum of activity, the market is categorised into narrow spectrum, broad spectrum, and extended spectrum. In 2022, the broad-spectrum segment witnessed the largest revenue share in the market. Infections of the throat, ear, nasal sinuses, respiratory tract (such as pneumonia), urinary tract, skin and soft tissue, and typhoid fever can all be treated with broad-spectrum penicillins, a class of antibiotics related to penicillin. Ampicillin and its esters, which include bacapicillin, pivampicillin, and talampicillin, as well as amoxycillin, co-amoxiclav, and mezlocillin are the major broad-spectrum penicillins.
Distribution Channel Outlook
On the basis of distribution channel, the market is fragmented into hospital pharmacies, drug stores & retail pharmacies, and online providers. The online providers segment projected a prominent revenue share in the market in 2022. Penicillin drugs are available through several online vendors, enabling consumers to find certain brands, doses, and formulations that suit their unique needs. Additionally, users can shop online at any time because of the platforms' 24/7 availability. These factors will lead the growth in this segment.
Route of Administration Outlook
Based on route of administration, the market is classified into oral, and parenteral. In 2022, the parenteral segment held the highest revenue share in the market. Due to the increased use of penicillin injections for the treatment of serious bacterial infections and the rise in syphilis prevalence, for which penicillin G injections are the primary treatment. Sometimes, parenteral administration is favored over other drug delivery methods, such as cardiac arrest and anaphylactic shock emergencies.
Regional Outlook
Region wise, the market is analysed into North America, Europe, Asia Pacific, and LAMEA. In 2022, the Asia Pacific region led the market by generating highest revenue share. The growth can be related to the region's rising incidence of infectious diseases and the rising demand for penicillin drugs. With the expanding populations of nations like China and India, the Asia-Pacific region is one of the greatest markets for antibiotics, including the penicillin drugs. Furthermore, the Asia-Pacific market has expanded significantly due to factors like rising healthcare costs, improved healthcare infrastructure, rising antibiotic usage knowledge, and the presence of major pharmaceutical companies in the region.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Pfizer, Inc., Novartis AG, Lupin Limited, Abbott Laboratories, Cipla Limited, Takeda Pharmaceutical Company Limited, Alkem Laboratories Ltd., Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd.
Recent Strategies Deployed in Penicillin Drug Market
Partnerships, Collaborations & Agreements:
Mar-2023: GlaxoSmithKline PLC signed a partnership with SCYNEXIS, Inc, a pharmaceuticals company based in the United States, to use SCYNEXIS' Brexafemme tablets. The addition of Brexafemme would strengthen GlaxoSmithKline's antibiotic portfolio.
Sep-2022: GlaxoSmithKline PLC partnered with Spero Therapeutics, Inc., a US-based biotech company, to use Spero's tebipenem pivoxil hydrobromide antibiotic drug. The partnership would allow GlaxoSmithKline to offer better treatment options for patients with urinary tract infections.
Apr-2022: Novartis AG announced a partnership with Sandoz, a Swiss pharmaceutical company, to develop solutions against antimicrobial resistance. The combined expertise of the two companies would pave the way for countering the threat of antimicrobial resistance (AMR).
Jan-2022: Pfizer, Inc. came into partnership with Becton, Dickinson, and Company, a biotech company based in the United States, to develop solutions for the correct use of antimicrobial drugs. The partnership would enable the customers of the two companies to benefit from better diagnosis and treatment.
Mar-2021: Cipla Limited entered a partnership with SIGA Technologies, Inc., a pharmaceutical company, to develop solutions for novel antibacterial drugs for countering biothreats. The combined expertise of the two companies would pave the way for biothreat treatment in the US market.
Mergers & Acquisition:
Jan-2023: Sun Pharmaceutical Industries Ltd. announced the acquisition of three brands namely, Disperzyme-CD, Disperzyme, and Phlogam from Aksigen Hospital Care, an Indian-based pharmaceutical company. The acquisition enhances the company's anti-inflammatory portfolio.
Dec-2022: Takeda Pharmaceutical Company Limited took over autoimmune disease treatment drugs from Nimbus Therapeutics, a therapeutics company based in the US. The acquisition builds up Takeda's therapeutic business.
Mar-2022: Pfizer, Inc. announced the acquisition of Arena Pharmaceuticals, an immuno-inflammatory disease specialist. The acquisition builds up the company's capability for immuno-inflammatory disease treatment.
Oct-2021: Novartis AG acquired the cephalosporin antibiotics division from GSK, a British biopharma company. The acquisition strengthens Novartis' foothold in the antibiotics market.
Product Launches and Product Expansions:
Jan-2023: Alkem Laboratories Ltd. introduced Zidavi, a novel anti-infective drug. The drug is made up of a mixture of avibactam and ceftazidime and has the main application in Urinary Tract Infections treatment.
Trials and Approvals:
Apr-2023: Pfizer, Inc. received approval from U.S. Food and Drug Administration for its PREVNAR 20. The PREVNAR 20 is a vaccine-based treatment for children, under 17 years of age, with pneumococcal disease.
Market Segments covered in the Report:
By Source
By Spectrum of Activity
By Distribution Channel
By Route of Administration
By Geography
Companies Profiled
Unique Offerings from KBV Research